Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,048.00
(
-1.01%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
109.55
(
1.31%
)
Bitcoin
68,564.40
(
1.07%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 165139

Thursday, 08/08/2013 10:45:06 PM

Thursday, August 08, 2013 10:45:06 PM

Post# of 257269
Did GSK settle with anyone other than Apotex? If not, GSK may continue to detail branded Lovaza until the CoM patent expires.

In any case, I don't think GSK is interested in Vascepa or AMRN, although they would like to see Vascepa get NCE status for the reason mentioned in my previous post.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today